Keyphrases
PDSA Cycle
83%
Iterative Cycle
83%
Quality Improvement Study
50%
Drug Trends
50%
Plan-Do-Study-Act
50%
Need for Improvement
50%
Incremental Testing
41%
Change Testing
41%
Cycle Life Prediction
41%
Transfemoral Amputation
40%
Pertrochanteric Fracture
35%
Sodium-glucose Cotransporter
33%
Clinical Healthcare
25%
Clinical Practice
25%
Healthcare
25%
Prediction-based
25%
CINAHL
25%
PubMed
25%
External Validity
25%
Internal Validity
25%
Healthcare Settings
25%
Embase
25%
Peer-reviewed Journals
25%
Updated Guidelines
25%
Inclusion Criteria
25%
Clinical Outcome
25%
SQUIRE
25%
Systematic Literature Review
25%
Healthcare System
25%
Methodological Characteristics
21%
Below-the-ankle
20%
Quality Improvement Methods
16%
Multimorbid
16%
Conference Abstracts
16%
Improper Use
16%
Public Savings
16%
High-cost Drugs
16%
Lower Limb Amputation
10%
Incidence of Amputation
10%
CORE Diabetes Model
8%
Comparator Choice
8%
Industry Sponsorship
8%
Sponsorship Bias
8%
Secondary Diabetes
7%
Plan-Do-Study-Act Cycle
7%
Cyclic Method
7%
Average Life Expectancy
7%
Practice Outcomes
7%
Quality Improvement Methodologies
7%
Medicine and Dentistry
Cohort Analysis
100%
Diabetes
61%
Maturity Onset Diabetes of the Young
50%
Sodium Glucose Cotransporter 2 Inhibitor
50%
Amputation
50%
Diabetic Ketoacidosis
50%
Diabetes Mellitus
50%
Retrospective Cohort Study
50%
Glucagon-Like Peptide-1 Agonist
30%
Insulin Dependent Diabetes Mellitus
16%
Population
10%
Secondary Diabetes
7%
Hazard Ratio
7%
Linear Regression Analysis
5%
Leg Amputation
5%
Least Square Analysis
5%
Survival Analysis
5%
Proportional Hazards Model
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
60%
Sodium Glucose Cotransporter 2 Inhibitor
58%
Antidiabetic Agent
50%
Effectiveness Study
50%
Rigor
50%
Cohort Study
50%
Diabetic Ketoacidosis
50%
Glucagon-Like Peptide-1
41%
Glucagon Like Peptide 1 Receptor Agonist
38%
Femur Pertrochanteric Fracture
27%
Semaglutide
16%
Dipeptidyl Peptidase IV
8%
Empagliflozin
8%
Dipeptidyl Peptidase IV Inhibitor
8%
Randomized Controlled Trial
8%